We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Theravance announced that the first patient has been treated in its Phase II clinical study of TD-1792, an investigational heterodimer antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).
Poniard Pharmaceuticals announced that it has reached a special protocol assessment (SPA) agreement with the FDA for its pivotal Phase III SPEAR trial of picoplatin for the treatment of small-cell lung cancer (SCLC).
Use of Alexion's pexelizumab immediately before and for 24 hours after stent placement or angioplasty for certain heart attack patients did not have any significant treatment effect compared with placebo, according to a study in the Jan. 3 issue of The Journal of the American Medical Association.
Amylin Pharmaceuticals and Eli Lilly announced that the FDA has approved Byetta (exenatide) injection as an add-on therapy to improve blood sugar control in people with Type 2 diabetes who have not achieved adequate control on a thiazolidinedione (TZD).